These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 30231682)

  • 1. Comparison of New Drug Accessibility and Price Between Japan and Major European Countries.
    Takayama A; Narukawa M
    Ther Innov Regul Sci; 2017 Sep; 51(5):604-611. PubMed ID: 30231682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmaceutical Pricing and Reimbursement in Japan: For Faster, More Complete Access to New Drugs.
    Takayama A; Narukawa M
    Ther Innov Regul Sci; 2016 May; 50(3):361-367. PubMed ID: 30227073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative Assessment of Premium Rates for Clinical Usefulness in New Drug Price Calculation in Japan.
    Takayama A; Kobayashi E; Nakamura T; Narukawa M
    Ther Innov Regul Sci; 2017 Sep; 51(5):582-588. PubMed ID: 30231680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. International Price Comparisons of Anticancer Drugs: A Scheme for Improving Patient Accessibility.
    Jung JH; Kim DJ; Suh K; You J; Lee JH; Joung KI; Suh DC
    Int J Environ Res Public Health; 2021 Jan; 18(2):. PubMed ID: 33466893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Universal Health Coverage and Cancer Drugs - A Cost-Effectiveness Perspective].
    Fukuda A; Igarashi A
    Gan To Kagaku Ryoho; 2016 Nov; 43(11):1311-1315. PubMed ID: 27899770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. European healthcare policies for controlling drug expenditure.
    Ess SM; Schneeweiss S; Szucs TD
    Pharmacoeconomics; 2003; 21(2):89-103. PubMed ID: 12515571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reimbursement Lag of New Drugs Under Taiwan's National Health Insurance System Compared With United Kingdom, Canada, Australia, Japan, and South Korea.
    Shih YR; Liao KH; Chen YH; Lin FJ; Hsiao FY
    Clin Transl Sci; 2020 Sep; 13(5):916-922. PubMed ID: 32166908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Formal Implementation of Cost-Effectiveness Evaluations in Japan: A Unique Health Technology Assessment System.
    Hasegawa M; Komoto S; Shiroiwa T; Fukuda T
    Value Health; 2020 Jan; 23(1):43-51. PubMed ID: 31952673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient access to pharmaceuticals: an international comparison.
    Cohen J; Faden L; Predaris S; Young B
    Eur J Health Econ; 2007 Sep; 8(3):253-66. PubMed ID: 17279403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An International Review of Health Technology Assessment Approaches to Prescription Drugs and Their Ethical Principles.
    Rand LZ; Kesselheim AS
    J Law Med Ethics; 2020 Sep; 48(3):583-594. PubMed ID: 33021189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New Drug Reimbursement and Pricing Policy in Taiwan.
    Chen GT; Chang SC; Chang CJ
    Value Health Reg Issues; 2018 May; 15():127-132. PubMed ID: 29704659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing patient access to pharmaceuticals in the UK and US.
    Cohen J; Cairns C; Paquette C; Faden L
    Appl Health Econ Health Policy; 2006; 5(3):177-87. PubMed ID: 17132032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of Health Technology Assessment in Drug Policies: Korea.
    Bae EY
    Value Health Reg Issues; 2019 May; 18():24-29. PubMed ID: 30419447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. National reimbursement listing determinants of new cancer drugs: a retrospective analysis of 58 cancer treatment appraisals in 2007-2016 in South Korea.
    Kim ES; Kim JA; Lee EK
    Expert Rev Pharmacoecon Outcomes Res; 2017 Aug; 17(4):401-409. PubMed ID: 28010146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. International comparison of the factors influencing reimbursement of targeted anti-cancer drugs.
    Lim CS; Lee YG; Koh Y; Heo DS
    BMC Health Serv Res; 2014 Nov; 14():595. PubMed ID: 25432511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does drug price-regulation affect healthcare expenditures?
    Ben-Aharon O; Shavit O; Magnezi R
    Eur J Health Econ; 2017 Sep; 18(7):859-867. PubMed ID: 27696009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The evolution of Taiwan's National Health Insurance drug reimbursement scheme.
    Hsu JC; Lu CY
    Daru; 2015 Feb; 23(1):15. PubMed ID: 25889754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationships between developmental strategies for additional indications and price revisions for anticancer drugs in Japan.
    Maeda H; Okabe A; Sakakura K; Ng DB; Akazawa M
    BMC Health Serv Res; 2021 Dec; 21(1):1329. PubMed ID: 34895223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. German Pharmaceutical Pricing: Lessons for the United States.
    Rodwin MA; Gerke S
    Int J Health Serv; 2022 Jan; 52(1):146-158. PubMed ID: 34668806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.